Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex F Herrera

Showing results (71-80 of 175) with videos related to

Pageof 18
Sort By:
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
British Journal of Haematology|May 26, 2024
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysisNarendranath Epperla, Hamza Hashmi, Kwang W Ahn, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
Leukemia|February 15, 2020
Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphomaJoo Y Song, Caoimhe Egan, Alyssa C Bouska, et al.
Pageof 18

Showing results (71-80 of 175) with videos related to

Sort By:
Pageof 18
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
British Journal of Haematology|May 26, 2024
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysisNarendranath Epperla, Hamza Hashmi, Kwang W Ahn, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
Leukemia|February 15, 2020
Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphomaJoo Y Song, Caoimhe Egan, Alyssa C Bouska, et al.
Pageof 18